Immunotherapy by ImmunityBio - Cancer Vaccine Research
ImmunityBio develops next-generation immunotherapies that activate both innate and adaptive immune responses to treat cancer and infectious diseases. Its lead product ANKTIVA received FDA approval in 2024 for non-muscle invasive bladder cancer, and the company applies a 'triangle offense' strategy stimulating NK cells, T cells, macrophages, and dendritic cells to create durable immune responses.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountDec 2025
Jul 2025
Jan 2025
Sep 2015
Create a free account to see which investors have funded this company.
Create Free Account
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Health insurance company using technology to make health care simple, affordable, and accessible.
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
